Bioton Turns Sights On Russia

Demonstrating commitment to expanding beyond its saturated domestic market, Polish biotechnology firm Bioton is planning to capture a sizeable share of the Russian insulin market following the approval of three of its recombinant human insulin products there. Additionally, the company has longer term plans to penetrate the Ukraine, Asia, Western Europe and even the US, eventually gaining 10% of the global market for

To read the full article, please choose one of the following options: